PEX3 and melanoma: In this present study, we showed that compromising peroxisome biogenesis by targeting PEX3 (or PEX19) sensitizes melanoma to MAPK pathway inhibition and overcomes MAPKi resistance, a phenotype that is more robust when UGCG is simultaneously inhibited.